-
A Breakthrough in Sjogren’s Disease Treatment: Amgen Reports Positive Phase 3 Results
NASDAQ: $AMGN New Hope for Patients There is exciting news for the autoimmune community as Amgen recently announced positive results from its Phase 3 clinical trial evaluating dazodalibep. This investigational therapy is being studied as a potential treatment for Sjogren’s disease, a chronic condition that often leaves patients struggling with severe dryness and systemic fatigue.…